Lumos Diagnostics Holdings (ASX:LDX) and Hologic agreed to expand the scope of work for the new fetal fibronectin test, according to a Monday Australian bourse filing.
The expanded scope of work relates to phase 3 of the development agreement, which focuses on delivery of the system prototype and will include the incorporation of additional hardware features into the proprietary reader technology.
This is expected to generate additional fee revenue for Lumos of between $600,000 to $800,000.
Phase 2 of the development agreement is expected to complete around April. The phase seeks to demonstrate that the assay can detect a biomarker.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。